PLEASANTON, Calif., June 18 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the Wells Fargo Securities Healthcare Conference on Thursday, June 24.
Gary F. Burbach, president and chief executive officer, will provide an update on the company, beginning at 10:15 a.m., Eastern Daylight Time (7:15 a.m., Pacific Daylight Time).
The presentation will be available through the conference web site at http://www.wsw.com/webcast/wa61/thor/, or on the company’s web site at http://www.thoratec.com.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company’s product lines include the Thoratec® VAD (Ventricular Assist Device) and HeartMate® LVAS (Left Ventricular Assist System) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company’s web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. CentriMag is a registered trademark of Levitronix, LLC.
SOURCE Thoratec Corporation
